Actavis

Parsippany Troy Hills, United States Founded: 1956 • Age: 70 yrs Listed Acquired By Teva Pharmaceuticals
Manufacturer of generic products

About Actavis

Actavis is a Healthcare company based in Parsippany Troy Hills (United States) founded in 1956, and was acquired by Teva Pharmaceuticals in July 2015. Manufacturer of generic products. Actavis has completed 7 acquisitions, including Allergan, Auden Mckenzie and Durata Therapeutics. Its Indian entity Actavis Pharma Development Centre Private Limited reported revenue of β‚Ή70.97 Cr. Its focus areas include Traditional Pharmaceuticals, Generics and Therapeutic Areas.

Company details

Actavis was founded in 1956 and is headquartered in Parsippany Troy Hills, United States. Operations focus on the pharmaceutical sector, with emphasis on generic drug production and distribution. The company acquired Allergan, leading to a name change to Allergan plc, though the U.S. and Canadian generics business continues under the Actavis brand. In 2013, annual revenues reached 5.91 billion, alongside a net profit of 0.09 billion.

Key Metrics
  • Indian entity revenue
    ₹70.97 Cr

    FY 2026 · +1% YoY

  • Indian entity net profit
    ₹7.13 Cr

    FY 2026 · 10% margin

  • Indian entity EBITDA
    ₹16.26 Cr

    FY 2026 · 24% margin

  • Investors
  • Investments & Acquisitions
    Allergan

    & 6 more

  • Acquired by

Funding Insights of Actavis

  • Total Rounds 1

All 1 funding rounds of Actavis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jun 2014Debt – Conventional––
–
Valuation history

1 investors in total: 1 institutional.

Investors in Actavis

Actavis has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Teva Pharmaceuticals.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
Generic pharmaceuticals are manufactured by Teva Pharmaceuticals.
1901tevapharm.comPetah Tikva, Israel
Premium access

Investor details for Actavis

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Actavis Pharma Development Centre Private Limited (Actavis)

Actavis Pharma Development Centre Private Limited is the primary company behind Actavis. The board of Actavis Pharma Development Centre Private Limited currently have 3 directors; the longest-serving is Sunilkumar Patloba Nagargoje, appointed in 2019. 18 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Sunilkumar Patloba Nagargoje
DIN 08623096
Director27 Nov 20196 yrs 11 moActavis Pharma Development Centre Private Limited
Vinod Narayan Shetty
DIN 09257187
Director25 Aug 20215 yrs 2 moActavis Pharma Development Centre Private Limited
Nishank Bhargava
DIN 09472446
Director23 Feb 20224 yrs 8 moActavis Pharma Development Centre Private Limited

Financials of Actavis

Figures of Actavis Pharma Development Centre Private Limited, the primary company behind Actavis, for FY 2026. Revenue was ₹70.97 Cr (+1% year on year). Net profit was ₹7.13 Cr (10% margin). EBITDA was ₹16.26 Cr (24% margin). Revenue has grown at a compounded annual rate of +15% over three years and +14% over five years.

  • ₹70.97 CrRevenue · FY 2026 · +1% YoY
  • ₹7.13 CrNet profit · 10% margin
  • ₹16.26 CrEBITDA · 24% margin
  • ₹13.02 CrPaid-up capital
  • 160Employees (provident fund records)
  • +15%Revenue CAGR, 3 years
  • +14%Revenue CAGR, 5 years

Balance sheet, profit and loss, cash flow and ratios of Actavis Pharma Development Centre Private Limited are on its company page.

Premium access

Detailed financial statements for Actavis

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Actavis

Actavis has strategically engaged in corporate development activities, having acquired 7 companies. Notable acquisitions include Allergan, Auden Mckenzie and Durata Therapeutics.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Developer of generic medicines
audenmckenzie.comCastleford, United Kingdom2001Jan 2015$467.68M
A portfolio of generic medicines is developed and manufactured.
allergan.comMadison, United States1948Nov 2014$70.5B
Novel antibiotics for infectious diseases are developed by the company.
duratatherapeutics.comChicago, United States2009Oct 2014β€’β€’β€’β€’
Drug development for gastroenterology disorders is conducted.
furiex.comMorrisville, United States2009Apr 2014$1.1B
Anti-allergic, metabolism, and other medical drugs are manufactured.
silommedical.co.thPhaya Thai, Thailand1946Apr 2014$100M
Pharmaceutical formulations are developed and marketed by Forest Laboratories.
frx.comNew York, United States1954Feb 2014β€’β€’β€’β€’
Contract research, development, and manufacturing for biologic drugs are offered.
wcrx.comRockaway, United States1999May 2013$8.5B
Premium access

Complete acquisition details for Actavis

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Actavis

11 dated milestones of Actavis across 59 years, from founding to its latest funding, stage changes and deals.

  1. Founded Actavis is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Acquisition Acquires Warner Chilcott.
  4. Acquisition Acquires Forest Laboratories.
  5. Acquisition Acquires Silom Medical.
  6. Acquisition Acquires Furiex.
  7. Funding First funding round.
  8. Acquisition Acquires Durata Therapeutics.
  9. Acquisition Acquires Allergan.
  10. Acquisition Acquires Auden Mckenzie.
  11. Exit Acquired by Teva Pharmaceuticals.

Web traffic of Actavis

Websites that share an audience with Actavis (actavis.com).

Similar websites

Websites whose visitors overlap most with Actavis. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
watson.com
watson.com
100%
#14,435,464–
pfizer.com
91%
1.9M#24,984View details
abcfarmaceutici.it
abcfarmaceutici.it
82%
#4,766,099–
baxteritalia.it
baxteritalia.it
82%
#3,157,074–
mylan.com
78%
26.4K#1,585,141View details
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 16 similar websites and full traffic analytics for Actavis

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 16 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Traditional Health & Nutrition

3 companies that operate in the same segment as Actavis (Traditional Health & Nutrition) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Manufacturer of generics formulations
2002Bridgewater, New Jersey, United StatesUSD 3.02 B8,300
Biosimilar therapeutics are developed for oncology and autoimmune diseases.
2010Redwood City, California, United StatesUSD 143.62 MUSD 42.17 M228
Ophthalmic pharmaceuticals and instruments are developed for eye care.
1853Bridgewater, New Jersey, United StatesUSD 5.1 B13,500
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Actavis

Premium access

Complete news archive for Actavis

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Actavis

Actavis was founded in 1956 and raised its 1st funding round 58 years after it was founded.

Actavis is headquartered in Parsippany Troy Hills, United States. It is registered at Parsippany Troy Hills, New Jersey, United States.

The primary company behind Actavis, Actavis Pharma Development Centre Private Limited, reported revenue of β‚Ή70.97 Cr for FY 2026, up 1% year on year.

Actavis was founded in 1956 and is headquartered in Parsippany Troy Hills, United States. Operations focus on the pharmaceutical sector, with emphasis on generic drug production and distribution. The company acquired Allergan, leading to a name change to Allergan plc, though the U.S. and Canadian generics business continues under the Actavis brand. In 2013, annual revenues reached 5.91 billion, alongside a net profit of 0.09 billion.

Actavis has made 7 acquisitions, including Allergan, Auden Mckenzie, and Durata Therapeutics.

Actavis has 1 investor. Key investors include Teva Pharmaceuticals.

Actavis operates through Actavis Pharma Development Centre Private Limited.

Yes. Actavis was acquired by Teva Pharmaceuticals in July 2015.

The legal entities of Actavis currently have 5 directors, including Sunilkumar Patloba Nagargoje, Shweta, Nishank Bhargava and others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available